SARS-CoV-2 neutralizing monoclonal antibodies : a potential breakthrough in the early treatment of Covid-19 in high-risk patients
Despite vaccination, a substantial proportion of immunocompromised patients have an increased risk for severe Covid-19. Treatment with SARS-CoV-2 neutralizing monoclonal antibodies has been shown to be safe and can prevent Covid-19 associated hospitalization and death. Monoclonal antibodies neutralize the virus and promote the immune response against SARS-CoV-2. Treatment with monoclonal antibodies is a potential breakthrough for the treatment of patients who are at high risk for severe disease when given early after infection. The first encouraging clinical trial data and the imminent availability of combination antibody therapy create a "momentum" to address several essential questions that are necessary to address for the structural use of this treatment in routine clinical care. These concern the real-world effect and sustainability of treatment of vulnerable patients, the optimal logistics and the cost-effectiveness of these novel compounds.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:165 |
|---|---|
| Enthalten in: |
Nederlands tijdschrift voor geneeskunde - 165(2021) vom: 07. Okt. |
| Sprache: |
Niederländisch |
|---|
| Weiterer Titel: |
SARS-CoV-2-antilichaamtherapie |
|---|
| Beteiligte Personen: |
de Bree, Godelieve J [VerfasserIn] |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 06.12.2021 Date Revised 14.12.2021 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM333914996 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333914996 | ||
| 003 | DE-627 | ||
| 005 | 20231225222630.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||dut c | ||
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM333914996 | ||
| 035 | |a (NLM)34854645 | ||
| 035 | |a (PII)D6173 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dut | ||
| 100 | 1 | |a de Bree, Godelieve J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 neutralizing monoclonal antibodies |b a potential breakthrough in the early treatment of Covid-19 in high-risk patients |
| 246 | 3 | 3 | |a SARS-CoV-2-antilichaamtherapie |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Despite vaccination, a substantial proportion of immunocompromised patients have an increased risk for severe Covid-19. Treatment with SARS-CoV-2 neutralizing monoclonal antibodies has been shown to be safe and can prevent Covid-19 associated hospitalization and death. Monoclonal antibodies neutralize the virus and promote the immune response against SARS-CoV-2. Treatment with monoclonal antibodies is a potential breakthrough for the treatment of patients who are at high risk for severe disease when given early after infection. The first encouraging clinical trial data and the imminent availability of combination antibody therapy create a "momentum" to address several essential questions that are necessary to address for the structural use of this treatment in routine clinical care. These concern the real-world effect and sustainability of treatment of vulnerable patients, the optimal logistics and the cost-effectiveness of these novel compounds | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 700 | 1 | |a Wiersinga, W Joost |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nederlands tijdschrift voor geneeskunde |d 1946 |g 165(2021) vom: 07. Okt. |w (DE-627)NLM000034231 |x 1876-8784 |7 nnns |
| 773 | 1 | 8 | |g volume:165 |g year:2021 |g day:07 |g month:10 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 165 |j 2021 |b 07 |c 10 | ||